Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › G-CSF

G-CSF

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of G-CSF

48 trials tracked of G-CSF: 4 in phase 3 or 4 and 2 with published results. The most-cited published study has 102 citations.

48Trials tracked
4Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 1 Phase 3 3 Phase 2 42 Phase 1 1 Other / NA 1
  1. Phase 3 A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma Completed · 102 cited
  2. Phase 3 Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome Completed · 43 cited
  3. Phase 4 Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma Completed
  4. Phase 3 Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma Completed
  5. Phase 2 G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients Completed
  6. Phase 2 Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization) Completed
Show 42 more trials
  1. Phase 2 Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients Completed
  2. Phase 2 Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas Completed
  3. Phase 2 Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML Completed
  4. Phase 2 Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma Completed
  5. Phase 2 Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma Completed
  6. Phase 2 Efficacy and Safety of Filgrastim in Alzheimer's Disease Completed
  7. Phase 2 Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma Completed
  8. Phase 2 Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies Completed
  9. Phase 2 RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia Completed
  10. Phase 2 Study of Bortezomib in Combination With Cyclophosphamide and Rituximab Completed
  11. Phase 2 Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia Completed
  12. Phase 2 Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage Completed
  13. Phase 2 Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia Completed
  14. Phase 2 Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia Completed
  15. Phase 2 Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome Completed
  16. Phase 2 Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma Completed
  17. Phase 2 Therapy for Children With Advanced Stage Neuroblastoma Completed
  18. Phase 2 Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS Completed
  19. Phase 2 Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma Completed
  20. Phase 2 Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies Completed
  21. Phase 2 Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT) Completed
  22. Phase 2 Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma Completed
  23. Phase 2 Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma Completed
  24. Phase 2 Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy Completed
  25. Phase 2 Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer Completed
  26. Phase 2 Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia Completed
  27. Phase 2 High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma Completed
  28. Phase 2 Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia Completed
  29. Phase 2 Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma Completed
  30. Phase 2 Hematopoietic Stem Cell Transplant in Devic's Disease Completed
  31. Phase 2 Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow Completed
  32. Phase 2 Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502) Completed
  33. Phase 2 Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning Completed
  34. Phase 2 Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma Completed
  35. Phase 2 Allogeneic Transplantation From Related Haploidentical Donors Completed
  36. Phase 2 Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide Completed
  37. Phase 2 Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503) Completed
  38. Phase 2 Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant Completed
  39. Phase 2 HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Completed
  40. Phase 2 Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG Completed
  41. Phase 1 A Study of the Safety and Effect of Repeated Administration of G-CSF on Hot Flashes in Postmenopausal Women Completed
  42. N/A Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies Completed

Showing the 48 most-cited and recently-updated of 48 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Low-dose chemotherapy shows no difference in remission but worse outcomes in KIT-mutated AML
Oncology RCT
Low-dose chemotherapy shows no difference in remission but worse outcomes in KIT-mutated AML Low-dose chemotherapy shows similar results for some children with leukemia
This retrospective secondary analysis of a multicenter randomized controlled trial evaluated low-dose chemotherapy (LDC) versus standard-dos…
A study of children with a specific type of leukemia found that lower doses of chemotherapy can be as effective as standard doses for many p…
Oct 9, 2026
Tocilizumab serves as first-line therapy for CRS in CAR-T and VST cellular immunotherapies
Diabetes & Endocrinology Guideline
Tocilizumab serves as first-line therapy for CRS in CAR-T and VST cellular immunotherapies New guidelines offer clear paths for managing CAR-T cell complications
This clinical guideline provides a framework for managing early complications in patients receiving CAR-T cell or virus-specific T-lymphocyt…
New clinical guidelines provide clear steps for managing serious side effects like cytokine release syndrome in patients receiving CAR-T cel…
Frontiers Aug 29, 2026